Adalimumab plus methotrexate lowers treatment failure 2-fold in pediatric Crohn’s

Combination therapy with adalimumab plus low-dose methotrexate induced a two-fold reduction of treatment failure among pediatric patients with Crohn’s disease, according to research published in Gastroenterology.“Tumor necrosis factor inhibitors (TNFi), including infliximab and adalimumab, are a mainstay of pediatric Crohn’s disease therapy; however, non-response and loss of response are common,” Michael D. Kappelman, MD, MPH, professor of pediatric gastroenterology at University of North Carolina at Chapel Hill, told Healio. “As combination therapy withRead More

Generated by Feedzy